RBA Wealth Management LLC Takes $5 Million Position in Becton, Dickinson and Company (NYSE:BDX)

RBA Wealth Management LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 20,727 shares of the medical instruments supplier’s stock, valued at approximately $4,997,000. Becton, Dickinson and Company makes up approximately 1.9% of RBA Wealth Management LLC’s holdings, making the stock its 22nd largest position.

Other institutional investors and hedge funds have also modified their holdings of the company. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company during the third quarter valued at $26,000. Sound Income Strategies LLC grew its stake in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $45,000. Abound Wealth Management boosted its holdings in shares of Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares during the period. Finally, Chilton Capital Management LLC lifted its holdings in Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 185 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BDX. Raymond James cut their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Stifel Nicolaus raised their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Evercore ISI lifted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Price Performance

NYSE:BDX traded down $0.70 during trading hours on Tuesday, reaching $239.82. 429,259 shares of the company’s stock were exchanged, compared to its average volume of 1,385,380. The company has a market capitalization of $69.31 billion, a P/E ratio of 52.96, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $262.23. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The business’s 50-day simple moving average is $237.14 and its two-hundred day simple moving average is $235.16.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.96 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.